L&C Bio Rides Wave of Good News as US Entry Seen as Key to Value

Neurocrine Biosciences Inc (NASDAQ:NBIX) Scores High in Affordable Growth Screen

The "Affordable Growth" strategy targets stocks with strong growth and reasonable valuations. Neurocrine Biosciences (NBIX) fits perfectly,

Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.

This could be a key move for future growth.

US biotechs turn secretive as they fear competition from rising Chinese industry

US biotechs turn tight-lipped on gene targets and pipelines as China's fast-follower threat intensifies, 20+ founders and investors tell End

CRE Strategies Could Help Preserve Value in Life Sciences Mergers & Acquisitions

While pharmaceutical companies acquire sponsor-backed biotech companies, corporate real estate teams are becoming more responsible for prese

Why CMC is Becoming the Competitive Advantage in Biotech

Life Sciences Market Trends Q2 2026

The life sciences market remains optimistic, supported by continued momentum in manufacturing, steady clinical trial activity and FDA approv